Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OSUR vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OSUR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 9–1 Matrix Metrics)

OSUR Overall Winner 6-Pillar Tally: OSUR 3 – 1 BMRA (2 Tie) Matrix Metrics: OSUR 9 – 1 BMRA

As of Nov 16, 2026, OraSure Technologies Inc (OSUR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OSUR carries a Unified Composite Score of 56.9/100 (HOLD) at $3.60 (40.0x Forward P/E, -58.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Technical & Structure Timing Caution: OSUR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OSUR vs BMRA
OSUR NASDAQ Head-to-Head Winner
OraSure Technologies Inc
Surgical & Medical Instruments & Apparatus
$3.60
-0.41% 1D
Market Cap $250.0M
TTM Revenue $116M
Forward P/E 40.0x
Beta / 30D Vol 1.25β · 78% Vol
Unified Composite Score
56.9 / 100 HOLD
Tech 68.0 Fund 58.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $3.74 · SMA50: $3.72
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (OSUR 3 – 1 BMRA)

Columns: Metric · OSUR · BMRA
1. Valuation Multiples OSUR
Forward P/E 40.0x N/M
Trailing P/E 40.0x N/M
PEG Ratio 6.19x N/M
EV / Revenue 2.2x 1.1x
2. Growth & Scale OSUR
Revenue Growth (YoY) +14.1% -8.3%
Earnings Growth (YoY) +29.6% +0.0%
TTM Revenue (USD) $116M $4.3M
Market Cap $250.0M $6.0M
3. Profitability & Quality OSUR
Gross Margin 43.1% 0.9%
Operating Margin -58.2% -125.2%
Net Profit Margin -41.7% -115.5%
Return on Equity (ROE) -14.5% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$58M EBITDA -$3.2M
Cash Flow Margin -50.2% EBITDA Mgn -73.5%
Net Cash / Leverage $4.45 Book/Sh · -14.5% ROE $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 47.6% (77th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OSUR (9) vs BMRA (1)
Institutional Metric OSUR BMRA Criterion Row Edge
Market Capitalization
Scale
$250.0M $6.0M Larger Scale OSUR
Trailing P/E Ratio
Valuation
40.0x N/M Lower Multiple OSUR
Forward P/E Ratio
Valuation
40.0x N/M Lower Multiple OSUR
Revenue Growth (YoY)
Growth
+14.1% -8.3% Higher Growth OSUR
Operating Margin (TTM)
Profitability
-58.2% -125.2% Higher Margin OSUR
Net Profit Margin
Profitability
-41.7% -115.5% Higher Margin OSUR
Return on Equity (ROE)
Capital Efficiency
-14.5% -113.8% Higher ROE OSUR
52-Week Range Position
Momentum
61% ($2–$5) 4% ($1–$3) Stronger Trend OSUR
Beta / 30D Volatility
Risk Regime
1.25β · 78% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
56.9 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite OSUR
Trailing 12M Revenue (USD)
Operating Scale
$116M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
43.1% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
6.19x PEG · 2.2x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M EBITDA ($4.45 Book/Sh · -14.5% ROE) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OSUR +28.05 pp
OSUR: -0.14% · BMRA: -28.19%
3M Horizon OSUR +13.1 pp
OSUR: -3.87% · BMRA: -16.97%
6M Horizon OSUR +60.73 pp
OSUR: +19.77% · BMRA: -40.96%
1Y Horizon OSUR +104.97 pp
OSUR: +58.11% · BMRA: -46.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OSUR vs BMRA. Trailing 12-month operating profitability (OSUR -58.2% vs BMRA -125.2%) and valuation multiples (OSUR 40.0x vs BMRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OSUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$116M
Gross Margin43.1%
Op. Margin-58.2%
ROE / Fwd P/E-14.5% · 40.0x
BMRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.3M
Gross Margin0.9%
Op. Margin-125.2%
ROE / Fwd P/E-113.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OSUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 47.6%
IV Percentile 77th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OSUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OSUR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $250.0M market capitalization and -58.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OSUR vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, OraSure Technologies Inc (OSUR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OSUR carries a Unified Composite Score of 56.9/100 (HOLD) at $3.60 (40.0x Forward P/E, -58.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Technical & Structure Timing Caution: OSUR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OSUR leads the Growth & Scale pillar: OSUR posts +14.1% YoY revenue growth and +29.6% YoY earnings growth on $116M TTM revenue (43.1% gross margin, -58.2% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). On trailing 12-month operating scale, OSUR generates $116M in USD-normalized revenue versus $4.3M for BMRA. In operating R&D and SG&A reinvestment, OSUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

OSUR screens cheaper on headline valuation multiples. OSUR trades at 40.0x Forward P/E, 40.0x Trailing P/E, 6.19x PEG, and 2.2x EV/Revenue (-50.2% EBITDA margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OSUR (-14.5% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, OSUR carries 47.6% implied volatility (77th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.25β · 78% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.